GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Conceptus, Inc. (CPTS) [hlAlert]

Rating:
Outperform
CPTS
up 90.54 %

Conceptus, Inc. (CPTS) rated Outperform with price target $20 by Northland Securities

Posted on: Thursday,  Jan 31, 2008  9:25 AM ET by Northland Securities

Northland Securities rated Outperform Conceptus, Inc. (NASDAQ: CPTS) on 01/31/2008, when the stock price was $16.28. Since
then, Conceptus, Inc. has gained 90.54% as of 06/05/2014's recent price of $31.02.
If you would have followed this Northland Securities's recommendation on CPTS, you would have gained 90.54% of your investment in 2317 days.

Conceptus, Inc. develops, manufactures and markets the Essure permanent birth control system, a medical device for women that is approved for marketing in the United States by the United States Food and Drug Administration (FDA). The Essure system uses a soft and flexible micro-insert that is delivered into a woman's fallopian tubes to provide permanent birth control by causing benign tissue in-growth that blocks the fallopian tubes. A properly placed Essure micro-insert and the subsequent tissue growth prohibits the egg from traveling through the fallopian tubes and therefore prevents fertilization. On January 7, 2008, the Company acquired all of the outstanding shares of Conceptus SAS. Through Conceptus SAS, it sells Essure directly in France and uses distributors to sell Essure throughout the rest of Europe.

Our equity research effort attempts to identify high potential small-cap investment ideas. We offer traditional sell-side research services with a particular focus on unearthing information that either supports or challenges our investment thesis. We strive to continuously provide our institutional client base with timely and insightful thinking.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/31/2008 9:25 AM Buy
None
16.28 20.00
as of 12/24/2008
1 Week up  9.41 %
1 Month up  19.01 %
3 Months down  -0.14 %
1 YTD down  -9.13 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy